Carta Biosciences

Executive Summary

Carta Biosciences (operating as Carta Genomics) is a UK-based genomics company advancing preimplantation genetic testing (PGT) for in-vitro fertilization (IVF). Its core innovation is a polygenic risk score (PGT-P) test that enables prospective parents to assess embryos for susceptibility to complex diseases such as diabetes, heart disease, and certain cancers. By integrating polygenic risk prediction into embryo selection, Carta aims to improve IVF outcomes and reduce the burden of hereditary diseases across generations. The company operates in the rapidly growing fertility genomics market, driven by increasing IVF rates and consumer demand for comprehensive genetic screening. As a private entity with no disclosed funding or valuation, Carta likely operates through laboratory services and partnerships with fertility clinics. Given the early-stage nature of polygenic embryo screening and the lack of public clinical data or regulatory endorsements, Carta’s current commercial adoption appears limited. However, the company’s focus on a novel application of polygenic risk scores positions it at the forefront of reproductive genomics. Success will depend on clinical validation, regulatory acceptance (e.g., UK HFEA or FDA equivalent), and competitive differentiation from established PGT providers. While the science holds promise, uncertainties around efficacy, ethical concerns, and market readiness temper near-term outlook. Carta’s ability to secure funding for validation studies and forge clinic partnerships will be critical to its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation study for PGT-P test50% success
• TBDRegulatory approval from UK HFEA for clinical use of polygenic risk scores in embryo selection20% success
• Q2 2026Partnership announcement with major IVF clinic network in Europe or US60% success